Halogenated Clozapine Composition for D4/5HT2A Selectivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antipsychotic drugs for mental disorders like schizophrenia and bipolar disorder have a wide variety of symptoms and progress variants, with unknown disease mechanisms, leading to significant side effects due to non-specific receptor interactions, particularly affecting D2, 5HT2A, H1, and M4 receptors.

Innovation Solution

Development of a pharmaceutical composition with a compound that acts as a selective antagonist of D4 and 5HT2A receptors, minimizing interaction with D2, H1, and M4 receptors, thereby reducing side effects and enhancing therapeutic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antipsychotic drugs block D2 receptors to achieve antipsychotic effect, then therapeutic effectiveness is improved, but side effects (convulsions, dyskinesia, akathisia) increase

Engineering Contradiction:

Improveantipsychotic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the dopamine receptor blockade function by selectively targeting D4 receptors instead of broadly blocking D2 receptors. The compound of formula (I) is designed to specifically bind to D4 receptors while minimizing interaction with D2 receptors, thereby achieving antipsychotic effects through D4 selective antagonism and avoiding D2-mediated side effects

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by creating a compound with specific molecular structure (formula (I) featuring a dibenzodiazepine core with particular substituent patterns) that confers selective affinity for D4 receptors. This structural design ensures the drug interacts preferentially with D4 receptors in the brain, providing localized therapeutic action at the receptor level while sparing other receptor systems

Inventive Principle:

Principle #3Local quality

2Reliability

If antipsychotic drugs block 5HT2A serotonin receptors to reduce hallucinations, then antihallucinatory effect is improved, but selectivity decreases and other side effects increase

Engineering Contradiction:

Improveantihallucinatory effectVSAvoidreceptor selectivity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The compound of formula (I) exhibits local quality through its specific molecular architecture that provides differential binding characteristics. The dibenzodiazepine structure with particular R1 and R2 substituents creates a binding profile that favors D4 and 5HT2A receptors over other receptor types, achieving selective antagonism at therapeutic doses

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes by modifying the molecular parameters of the antipsychotic compound (specifically the substituents on the dibenzodiazepine ring system) to alter receptor binding affinity. This structural optimization adjusts the drug's pharmacological parameters to achieve preferential binding at D4 and 5HT2A receptors while reducing off-target effects

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If antipsychotic drugs block H1 histamine receptors to treat insomnia, then sedative effect is improved, but excessive sedation and reduced productivity occur

Engineering Contradiction:

Improveinsomnia treatmentVSAvoiddaily functioning

Core Design Contradiction:

Ease of operationVSProductivity

Solution Approach 1:

The patent segments the sedative function by designing a compound that selectively targets 5HT2A receptors rather than broadly blocking H1 histamine receptors. The selective 5HT2A antagonism provides calming and sleep-promoting effects through serotonin system modulation while avoiding the excessive sedation and cognitive impairment associated with H1 receptor blockade

Inventive Principle:

Principle #1Segmentation

4Object-affected harmful factors

If antipsychotic drugs block M4 muscarinic receptors to reduce salivation, then sialorrhea is improved, but cognitive side effects worsen

Engineering Contradiction:

ImprovesialorrheaVSAvoidcognitive function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent segments the cholinergic system interaction by designing a compound that does not significantly interact with M4 muscarinic receptors. The selective D4 and 5HT2A receptor antagonism achieves therapeutic effects without engaging the muscarinic cholinergic system, thereby avoiding both sialorrhea and cognitive impairment that result from M4 receptor blockade

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS12403143B2Pharmaceutical composition for treating functional psychiatric disorders

Publication Date: 2025.09.02 OBSHCHESTVO S OGRANICHENNOJ OTVETABTVENNOSTJU VALENTEK

AI summary

The group of inventions relates to medicine, pharmacology, namely to psychiatry and can be used for effective and safe treatment of mental disorders associated with dysfunction of dopamine and serotonin (5-hydroxytryptamine) neurotransmitter systems. Pharmaceutical compositions containing halogenated clozapine, in an amount effective as selective antagonists of D4 and 5NT2A receptors, and at least one pharmaceutically acceptable carrier, as well as their use and methods of treatment are offered for this purpose. The inventions make it possible to create a new drug with a well-balanced receptor profile, the intake of which will allow to treat mental disorders in an effective way without causing side effects associated with exposure to receptors that are not involved in the pathology of a mental disorder.